TriVascular, manufacturer of the Ovation Prime Abdominal Stent Graft System has announced the pricing of its initial public offering of 6,500,000 shares of its common stock at a public offering price of US$12.00 per share.
In addition, TriVascular has granted the underwriters a 30-day option to purchase up to an additional 975,000 shares of common stock at the same price. The company’s shares are expected to begin trading on The NASDAQ Global Select Market on 16 April 2014 under the ticker symbol “TRIV.” The offering is expected to close on 22 April 2014, subject to customary closing conditions.
J P Morgan Securities and Credit Suisse Securities (USA) are acting as joint book-running managers for the offering. Canaccord Genuity and Stifel, Nicolaus & Company are acting as co-managers.
A registration statement relating to the securities being sold in this offering was declared effective by the Securities and Exchange Commission on 15 April. A press release from the company makes it clear that this release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful, prior to registration or qualification under the securities laws of any such state or jurisdiction.
The offering will be made only by means of a prospectus. When available, copies of the final prospectus may be obtained from JP Morgan Securities, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at +1 (866) 803 9204, or from Credit Suisse Securities (USA), Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, by telephone at +1 (800) 221 1037 or by email at email@example.com.